个人情况介绍、概览

戴荣华，女，教授，博士研究生导师。1991年毕业于沈阳药学院,获化学制药学士学位,1996年于同校获药物分析学硕士学位，2004年获药物分析学博士学位。2009-2010年美国哈佛医学院Massachusetts General Hospital、Mclean Hospital访问学者。作为项目负责人先后主持了国家自然科学基金面上项目2项，国家“十一五科技支撑计划”子课题，辽宁省自然科学基金,辽宁省教育厅课题，校归国人员科研启动基金等；另外，参加了国家自然科学基金面上项目，国家科技部中药现代化研究项目，完成新药质量标准研究项目等多项。共发表论文40余篇，其中SCI收载28篇(第一、通讯)。

主要研究方向

研究方向一：中药药效物质基础

研究方向二：体内药代动力学的研究

研究方向三：药品质量标准研究

主持、参与的科研项目（含科研获奖等情况）

1.基于COX和LOX双靶点调控的滋肾丸治疗前列腺增生的物质基础及作用机制研究, 国家自然科学基金面上项目，基金编号81872987（负责人）

2.基于体内动态靶向效应的复方活络效灵丹抗炎药效物质基础研究，国家自然科学基金面上项目，基金编号81373924（负责人）

3.苍术饮片麸炒技术和相关设备研究，国家“十一五科技支撑计划，基金编号2006BAI09B06-01-06（子课题负责人）

4.滋肾丸干预前列腺增生（BPH）大鼠体内花生四烯酸代谢组学研究, 辽宁省自然科学基金，项目编号201602690（负责人）

5.关龙胆等中药材中农药多残留分析技术的研究，辽宁省教育厅课题，基金编号：20060881（负责人）

近年来发表代表性论文(限第一作者或通讯作者，SCI须写明影响因子)

1.Siqi Wang, David Yue-wei Lee, Ying Shang, Jun Liao, Xiaotong Cao, Linlin Xie,Teng

Zhang,Jing Liu,Ronghua Dai*.The Bioactive Alkaloids Identifiedfrom Cortex PhellodendriAmeliorate Benign Prostatic Hyperplasiavia LOX-5/COX-2 Pathway.Phytomed.2021 Dec;93:153813.doi:10.1016/j.phytomed.2021.153813.(IF= 5.34)

2.Bing Zhang, Yulin Duan, Yuwei Yang, Qing Mao, Fengwei Lin, Jun Gao,Xiwen Dai, Peng

Zhang , Qiuhua Li , Jinxin Li,Ronghua Dai*,Shaojie Wang*.Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthineoxidase inhibitors.Eur J Med Chem.2021 Oct19;227:113928.doi:10.1016/j.ejmech.2021.113928. (IF= 6.514)

3.Linlin Xie, David Yue-wei Lee, Ying Shang, Xiaotong Cao, Siqi Wang, Jun Liao, Teng

Zhang,Ronghua Dai*.Characterization of spirostanol glycosides and furostanol glycosides fromanemarrhenae rhizoma as dual targeted inhibitors of 5-lipoxygenase andCyclooxygenase-2 by employing a combination of affinity ultrafiltration andHPLC/MS.Phytomed.2020,Oct77:153284.doi:10.1016/j.phymed.2020.153284.(IF= 5.34)

4.Siqi Wang, Jiaxin Huai, Ying Shang, Linlin Xie, Xiaotong Cao, Jun Liao, Teng Zhang,

Ronghua Dai*.Screening for natural inhibitors of 5-lipoxygenase from Zi-shen pill extractby affinity ultrafiltration coupled with ultra performance liquidchromatography-mass spectrometry.J.Ethnopharmacol.2020,May 23;254:112733.doi:10.1016/j.jep.2020.112733.(IF= 3.69)

5.Xiaotong Cao, Ying Shang, Weigui Kong, Shuqing Jiang, Jun Liao,Ronghua Dai*.

Flavonoids Derived From Anemarrhenae Rhizoma Ameliorate Inflammation of Benign Prostatic Hyperplasia via Modulating COX/LOX Pathways.J.Ethnopharmacol.2021,Nov 2;284:114740.doi:10.1016/j.jep.2021.114740.(IF= 4.36)

6.HuaiJ,Zhao X,Wang S,Xie L,Li Y,Zhang T,Cheng C,Dai R*.Characterising and screening

cyclooxygenase-2 inhibitors from Zi-shen pill via affinity ultrafiltration-ultra performance liquid chromatography-mass spectrometry.J.Ethnopharmacol.2019,Sep 15;241:111900.

doi:10.1016/j.jep.2019.111900.(IF= 3.414)

7.Nannan Wang, Xiaoning Zhao, Weihui Wang, Yan Peng, Kaishun Bi,RonghuaDai*.Targeted

profiling of arachidonic acid and eicosanoids in rat tissue by UFLC–MS/MS: Application to identify potential markers for rheumatoid arthritis. Talanta.2017,Jan 1;162:479-487(IF= 4.244)

8.Li Y,Zhang T,Huai J,Cheng C,Xie L,Wang S,Dai R*.Metaboliteprofilingofl-isocorypalmine

inraturine,plasma, andfecesafteroraladministrationusinghighperformanceliquidchromatographycoupledtoFouriertransformioncyclotronresonancemassspectrometry. J Sep Sci.2019,Jan 42(2):619-627.(IF= 2.557)

9.Nannan Wang, Xiaoning Zhao , Congcong Cheng, Jiaxin Huai, Yiran Li, Kaishun Bi ,

Ronghua Dai*.Arachidonic acid metabonomics study for understanding therapeutic mechanism of Huo Luo Xiao Ling Dan on rat model of rheumatoid arthritis.J Ethnopharmacol.2018,May 10;217:205-211.(IF=3.115)

10.Qiaoxia Bian, Wang Weihui , Wang Nannan, Peng Yan, Ma Wen,Dai Ronghua*. Arachidonic

acid metabolomic study of BPH in rats and theinterventional effects of Zishen pill, a traditional Chinese medicine.J Pharm Biomed Anal.2016, 128:149-157.(IF=3.255)